Canakinumab
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 60 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI), Novartis
- Tags
- Monoclonal Antibody
- Trial Type
- Treatment
- Last Update
- 2 days ago
- SparkCures ID
- 1517
- NCT Identifier
- NCT04239157
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.